ES2173289T3 - Fgf9 como ligando especifico para fgfr3. - Google Patents

Fgf9 como ligando especifico para fgfr3.

Info

Publication number
ES2173289T3
ES2173289T3 ES96917641T ES96917641T ES2173289T3 ES 2173289 T3 ES2173289 T3 ES 2173289T3 ES 96917641 T ES96917641 T ES 96917641T ES 96917641 T ES96917641 T ES 96917641T ES 2173289 T3 ES2173289 T3 ES 2173289T3
Authority
ES
Spain
Prior art keywords
fgfr3
bone
progenitor cells
skeletal progenitor
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96917641T
Other languages
English (en)
Inventor
Avner Yayon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2173289T3 publication Critical patent/ES2173289T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION CONCIERNE AL FACTOR DE CRECIMIENTO DE LOS FIBROBLASTOS 9 (FGF9) COMO UN LIGANDO DE ALTA AFINIDAD PARA EL RECEPTOR 3 DEL FACTOR DE CRECIMIENTO DE LOS FIBROBLASTOS (FGFR3), EL CUAL LIGANDO ES CAPAZ DE UNIRSE A Y ACTIVAR EL FGFR3 DE MANERA ESPECIFICA. LA PRESENTE INVENCION SE DIRIGE TAMBIEN A METODOS PARA LA DETECCION DE FGFR3 UTILIZANDO FGF9, ASI COMO A LOS COMPUESTOS FARMACEUTICOS PARA MODULAR LA ACTIVIDAD DE FGFR3 QUE COMPRENDEN FGF9 COMO UN INGREDIENTE ACTIVO, ANTAGONISTAS DE O AGENTES QUE SE UNEN A FGF QUE SON CAPACES DE NEUTRALIZAR EL FGF9 NATIVO CIRCULANTE. LA PRESENTE INVENCION CONCIERNE TAMBIEN A NUEVOS FGF9 RECOMBINANTES DE RATON Y POLLO, VECTORES DE EXPRESION CONTENIENDO ESTOS FGF9 RECOMBINANTES Y UN ANIMAL TRANSGENICO TRANSFORMADO CON LOS MENCIONADOS VECTORES DE EXPRESION.
ES96917641T 1995-06-12 1996-06-12 Fgf9 como ligando especifico para fgfr3. Expired - Lifetime ES2173289T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13795P 1995-06-12 1995-06-12

Publications (1)

Publication Number Publication Date
ES2173289T3 true ES2173289T3 (es) 2002-10-16

Family

ID=21690089

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96917640T Expired - Lifetime ES2183957T3 (es) 1995-06-12 1996-06-12 Fgfr3 como marcador para celulas progenitoras del mesenquima esqueletico.
ES96917641T Expired - Lifetime ES2173289T3 (es) 1995-06-12 1996-06-12 Fgf9 como ligando especifico para fgfr3.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96917640T Expired - Lifetime ES2183957T3 (es) 1995-06-12 1996-06-12 Fgfr3 como marcador para celulas progenitoras del mesenquima esqueletico.

Country Status (12)

Country Link
US (2) US6447783B1 (es)
EP (3) EP0836380B1 (es)
JP (3) JPH11507828A (es)
CN (1) CN1195982A (es)
AT (2) ATE213590T1 (es)
AU (2) AU715996B2 (es)
CA (2) CA2223701C (es)
DE (2) DE69624239T2 (es)
DK (2) DK0833620T3 (es)
ES (2) ES2183957T3 (es)
IL (2) IL122473A (es)
WO (2) WO1996041523A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617242B2 (en) 2001-05-25 2013-12-31 Conformis, Inc. Implant device and method for manufacture
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US7618451B2 (en) 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US7799077B2 (en) 2002-10-07 2010-09-21 Conformis, Inc. Minimally invasive joint implant with 3-dimensional geometry matching the articular surfaces
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US8083745B2 (en) 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US6136040A (en) * 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
DE69941304D1 (de) 1998-09-14 2009-10-01 Univ R Zustandsbestimmung eines gelenks und schadenvorsorge
US20020058036A1 (en) * 1999-07-27 2002-05-16 Michael Jeffers Novel fibroblast growth factor and nucleic acids encoding same
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
DE122010000021I1 (de) 1999-10-06 2012-09-06 Tigenix Nv In vivo assay zur prüfung der phänotypischen stabilität
DK1282690T3 (da) 1999-10-06 2005-02-28 Tigenix Nv Isolation af precursorceller og anvendelse deraf til vævsreparation
WO2001060850A1 (en) * 2000-02-14 2001-08-23 Smithkline Beecham Corporation Novel compounds
US20020037557A1 (en) 2000-03-13 2002-03-28 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
EP1322224B1 (en) 2000-09-14 2008-11-05 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
WO2002022014A1 (en) 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
WO2002063037A2 (en) * 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
JP2005504563A (ja) 2001-05-25 2005-02-17 イメージング セラピューティクス，インコーポレーテッド 関節を再表面化する方法および組成物
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AU2003214601A1 (en) * 2002-03-14 2003-09-22 Yeda Research And Development Co. Ltd. Compositions and methods for inducing and regulating bone formation
WO2004022095A1 (en) * 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
WO2004043305A1 (en) 2002-11-07 2004-05-27 Conformis, Inc. Methods for determing meniscal size and shape and for devising treatment
AU2011211453B2 (en) * 2004-06-21 2015-01-15 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
CA2580975A1 (en) * 2004-09-24 2006-03-30 Angioblast Systems, Inc. Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
US7391676B2 (en) * 2004-12-22 2008-06-24 Asml Netherlands B.V. Ultrasonic distance sensors
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
EP2649951A3 (en) 2006-02-06 2013-12-25 ConforMIS, Inc. Patient selectable joint arthroplasty devices and surgical tools
US8500740B2 (en) 2006-02-06 2013-08-06 Conformis, Inc. Patient-specific joint arthroplasty devices for ligament repair
EP2119767B1 (en) 2007-01-23 2016-01-20 Yokohama City University Method for preparation of cartilage cell
WO2008157412A2 (en) 2007-06-13 2008-12-24 Conformis, Inc. Surgical cutting guide
WO2009111626A2 (en) 2008-03-05 2009-09-11 Conformis, Inc. Implants for altering wear patterns of articular surfaces
JP2011519713A (ja) 2008-05-12 2011-07-14 コンフォーミス・インコーポレイテッド 面関節および他の関節の治療のためのデバイスならびに方法
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US12383287B2 (en) 2009-02-24 2025-08-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
EP2405865B1 (en) 2009-02-24 2019-04-17 ConforMIS, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
EP2509539B1 (en) 2009-12-11 2020-07-01 ConforMIS, Inc. Patient-specific and patient-engineered orthopedic implants
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2754419B1 (en) 2011-02-15 2024-02-07 ConforMIS, Inc. Patient-adapted and improved orthopedic implants
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
MX2015002959A (es) 2013-03-10 2015-06-05 Univ Nagoya Nat Univ Corp Agente terapeutico para padecimiento sistemico oseo y uso del mismo.
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
US12108959B2 (en) 2019-05-29 2024-10-08 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
EP4044941A4 (en) 2020-01-17 2023-11-15 Wright Medical Technology, Inc. GUIDANCE TOOLS, SYSTEMS AND METHODS
WO2022182430A1 (en) 2021-02-24 2022-09-01 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
US12582421B2 (en) 2022-05-13 2026-03-24 Wright Medical Technology, Inc. Intraoperative adjustable guides, systems, and methods
CN116162589B (zh) * 2022-12-30 2025-10-03 西北工业大学 干细胞及其制备方法和应用、及标记组合物及其应用
US12569355B2 (en) 2023-08-31 2026-03-10 Wright Medical Technology, Inc. Systems and methods for total ankle arthroplasty

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
EP0608546A3 (en) 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
WO1994021813A1 (en) * 1993-03-17 1994-09-29 The Whittier Institute For Diabetes And Endocrinology Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Also Published As

Publication number Publication date
EP0836380B1 (en) 2002-02-27
IL122473A0 (en) 1998-06-15
IL122472A0 (en) 1998-06-15
US20020193309A1 (en) 2002-12-19
IL122472A (en) 2003-11-23
EP0833620A1 (en) 1998-04-08
WO1996041523A1 (en) 1996-12-27
JP2004305221A (ja) 2004-11-04
DE69624239T2 (de) 2003-07-10
EP0836380A1 (en) 1998-04-22
US6447783B1 (en) 2002-09-10
AU6014496A (en) 1997-01-09
EP1342476A2 (en) 2003-09-10
DE69624239D1 (de) 2002-11-14
AU715996B2 (en) 2000-02-17
CA2223701C (en) 2010-02-16
WO1996041620A1 (en) 1996-12-27
ATE213590T1 (de) 2002-03-15
AU6014596A (en) 1997-01-09
EP1342476A3 (en) 2003-09-17
CA2224229A1 (en) 1996-12-27
EP0836380A4 (en) 1999-03-31
JPH11507828A (ja) 1999-07-13
EP0833620A4 (es) 1998-05-06
EP0833620B1 (en) 2002-10-09
CN1195982A (zh) 1998-10-14
DK0833620T3 (da) 2003-01-13
JP3673281B2 (ja) 2005-07-20
IL122473A (en) 2003-11-23
ES2183957T3 (es) 2003-04-01
CA2223701A1 (en) 1996-12-27
DK0836380T3 (da) 2002-04-22
JPH11508358A (ja) 1999-07-21
DE69619526T2 (de) 2002-10-31
ATE225652T1 (de) 2002-10-15
DE69619526D1 (de) 2002-04-04
AU721773B2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
DK0833620T3 (da) FGFR3, en markør for mesenkymale progenitorceller
BR0313197A (pt) Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
DE69628290D1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE198980T1 (de) Bioabbaubare polymere zur zelltransplantation
DK1242401T3 (da) Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
BR0214217A (pt) Aumento de função de órgão
ATE296642T1 (de) Reverse-phase zusamensetzung zur bindegewebsreparatur
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
YU7797A (sh) Kombinovana terapija za osteoporozu
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
YU8904A (sh) Heterociklična jedinjenja zasnovana na n6-supstituisanom adeninu, postupci izrade,njihova upotreba za izradu lekova, kozmetičkih preparata i regulatora rasta, farmaceutski preparati, kozmetički preparati i regulatori rasta koji sadrže ova jedinjenja
AU3142597A (en) Dha-pharmaceutical agent conjugates
NO953781L (no) Terapeutisk anvendelse av keratinocyttvekstfaktor
TR199901433T2 (xx) Pirolo$3,4-D] pirimidinon t�revleri ve bunlar�n ila� olarak kullan�mlar�.
ES2150902T3 (es) Procedimientos para potenciar la cicatrizacion de heridas y la reparacion de tejidos.
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
PL361732A1 (en) Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 836380

Country of ref document: ES